Dual Antigen Targeting with Talquetamab plus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 20, 2025 799 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline ESMO Shares Recommendations to Support Cancer Research and Clinical Trials in Europe MOST POPULAR Food for thought: new insights into how chemotherapy causes cachexia June 15, 2022 Development of T-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy July 22, 2024 Stopping TKI Treatment Is Safe, Improves Quality of Life for Some... December 15, 2020 The Impact of COVID-19 on Black and Hispanic People with Cancer:... October 5, 2020 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Fruquintinib Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves... FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients...
